alfuzosin hydrochloride / Generic mfg. - LARVOL DELTA

An eco-friendly HPLC method for the sustainable analysis of the newly approved combinations of Alfuzosin and Tamsulosin, with Tadalafil in organic-solvent-free mixed-micellar systems. (PubMed, Analyst) - "Greenness of the method was assessed using the Analytical GREEnness metric approach (AGREE), and the blueness was assessed using blue applicability grade index (BAGI), with scores of 0.76 and 82.5, respectively. These scores underline the superiority of the proposed procedure over previously reported methods."

Journal • Benign Prostatic Hyperplasia • Urology

Electromotive Drug Administration (EMDA) in the Porcine Ureter: First Report of In Vivo Ureteral Dilation Following Alfuzosin Infusion (AUA 2025) - "Ureteral infusion of AFZ using EMDA resulted in higher levels of drug penetration and a significant increase in porcine ureteral distensibility."

Preclinical

The Beneficial Effects of Alpha-Blockers, Antimuscarinics, Beta 3-Agonist, and PDE5-Inhibitors for Ureteral Stent-Related Discomfort: A Systematic Review and Meta-Analysis from KSER Update Series. (PubMed, Medicina (Kaunas)) - "This study utilized a network meta-analysis to evaluate stent-related discomfort (SRD) in patients with alpha-blockers (alfuzosin, tamsulosin, and silodosin), antimuscarinics (solifenacin), beta 3-agonists (mirabegron), and phosphodiesterase 5-inhibitors (tadalafil) versus a placebo. Compared with the placebo, solifenacin, tamsulosin, and alfuzosin significantly decreased the USS. In our study, solifenacin may be considered the most effective medication for SRD."

Clinical • Journal • Retrospective data • Review • Renal Calculi • Urolithiasis • Urology

α-Adrenoreceptor blocker phentolamine inhibits voltage-gated sodium channels via the local anaesthetic binding site. (PubMed, Br J Pharmacol) - "Phentolamine blocks voltage-gated sodium channels via the local anaesthetic receptor site. This may conflict with its current indication as an antidote for local anaesthetics. We propose alternative α-adrenoreceptor antagonists as possible candidates for local anaesthetic reversal because these are less potent inhibitors of both cardiac and neuronal voltage-gated sodium channels."

Journal • Anesthesia • Pain • NAV1

Drug-induced dementia: a pharmacovigilance analysis of the FAERS database. (PubMed, Expert Opin Drug Saf) - "Besides neurological drugs, the drugs with the highest number of reports are apixaban, valsartan and atorvastatin. We found that tamsulosin, alfuzosin, and megestrol may be associated with an increased risk of dementia, and further research is required to clarify these relationships. In clinical practice, it is important to monitor the cognitive status of patients when using drugs that may increase the risk of dementia."

Adverse events • Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia

Alpha-adrenergic antagonists and iris dynamics: Challenges and solutions in cataract surgery. (PubMed, BMC Ophthalmol) - "α1-ARAs have implications for pupil size regulation and surgical procedures involving the eye. Tamsulosin is more potent than alfuzosin in inducing IFIS. Systemic α1-ARAs lower values of DMR thickness, DMR/SMR ratio and reduces pupillary diameter. Therefore, ophthalmologists, primary care physicians, urologists, and patients should be aware of the potential difficulties that these drugs pose for cataract surgery."

Journal • Surgery • Benign Prostatic Hyperplasia • Cardiovascular • Cataract • Hypertension • Ophthalmology • Urology • ADRA1B

Association Between Alpha-1 Adrenoreceptor Antagonist Use and Cognitive Impairment: A Systematic Review. (PubMed, Int Neurourol J) - "Tamsulosin was associated with no cognitive dysfunction in 2 RCTs, increased risk for dementia in 2 non-RCTs, no change in cognition in 1 non-RCT, and decreased risk for dementia in 1 non-RCT. Among 3 non-RCTs analyzing alfuzosin, it was associated with decreased risk of or no association with dementia in 2 studies and increased risk for dementia in 1 study. Doxazosin, prazosin, and terazosin were neutral or showed a negative risk for dementia...Considering the existing literature, it is appropriate to use α1-AR antagonists without concern for cognitive dysfunction. Future research, through robust study designs considering the multifactorial nature of cognitive dysfunction, is required to further evaluate this association."

Journal • Review • Alzheimer's Disease • Benign Prostatic Hyperplasia • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Hypertension • ADRA1B

Clinical features and management approaches for Urinary Incontinence in Older Adults: Evidence from Three Hospitals in Qatar. (PubMed, Nepal J Epidemiol) - "Solifenacin (24.9%), Tolterodine (4.1%), and Oxybutynin (1.1%) were the most commonly administered anticholinergic drugs, while Tamsulosin (82.9%), Alfuzosin (14.5%), and Doxazosin (1.7%) were the most frequently prescribed alpha-blockers. This study also highlights the need for thorough documentation of the diagnosis and reasons for improving the standards of patient care. The findings of this study provide important information that can be used to design medication management methods for enhancing patient outcomes."

Journal • Geriatric Disorders • Urinary Incontinence • Urology

Tamsulosin use in benign prostatic hyperplasia and risks of Parkinson's disease, Alzheimer's disease and mortality: An observational cohort study of elderly Medicare enrollees. (PubMed, PLoS One) - "The study analyzed 1.1 million patients for a mean follow-up period of 3.1 years from being prescribed one of the study drugs. For all outcomes, patients on tamsulosin were used as the reference for comparison. For mortality, alfuzosin was associated with 27% risk reduction (HR 0.73, 95%CI 0.68-0.78), and doxazosin with 6% risk reduction (HR 0.94, 95%CI 0.91-0.97). For Parkinson's disease, terazosin was associated with 26% risk reduction (HR 0.74, 95%CI 0.66-0.83), and doxazosin with 21% risk reduction (HR 0.79, 95%CI 0.72-0.88). For Alzheimer's disease, terazosin was associated with 27% risk reduction (HR 0.73, 95%CI 0.65-0.82), and doxazosin with 16% risk reduction (HR 0.84, 95%CI 0.76-0.92). Tadalafil was associated with risk reduction (27-40%) in all 3 outcomes. More research is needed to elucidate the underlying mechanisms of these observations. Given the availability of safer alternatives for treating benign prostatic hyperplasia, caution should be..."

Journal • Medicare • Observational data • Reimbursement • US reimbursement • Alzheimer's Disease • Benign Prostatic Hyperplasia • CNS Disorders • Movement Disorders • Parkinson's Disease

Synthesis of diversely substituted quinazoline-2,4(1H,3H)-diones by cyclization of tert-butyl (2-cyanoaryl)carbamates. (PubMed, Org Biomol Chem) - "This strategy can be utilized for the simplified synthesis of goshuyuamide II and an alkaloid isolated from Zanthoxylum arborescens in good yields. This method was also applied to the synthesis of quinazoline-2,4(1H,3H)-diones that are precursors of medicinally important compounds: alfuzosin, terazosin, prazosin, IAAP, doxazosin, FK 366 (zenarestat) and KF31327."

Journal

Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men. (PubMed, Neurology) - "We find an association in men who are taking Tz/Dz/Az and a lower hazard of DLB compared with similar men taking other medications. When combined with the literature of Tz/Dz/Az on Parkinson disease, our findings suggest that glycolysis-enhancing drugs may be broadly protective in neurodegenerative synucleinopathies. A future randomized trial is required to assess these associations for causality."

Journal • Alzheimer's Disease • Benign Prostatic Hyperplasia • CNS Disorders • Cognitive Disorders • Dementia • Lewy Body Disease • Movement Disorders • Parkinson's Disease

Risk of Parkinson's disease among users of alpha-adrenergic receptor antagonists: a systematic review and meta-analysis. (PubMed, Ann Med Surg (Lond)) - "The objective of the study is to compare the risk of Parkinson's disease (PD) between terazosin/alfuzosin/doxazosin (TZ/AZ/DZ) users and tamsulosin users. The risk of occurrence of PD was significantly lower in patients taking TZ/AZ/DZ than tamsulosin (n= 610,363, HR = 0.82, 95% CI = 0.71-0.94, P = 0.01; I2 = 87.4%). This meta-analysis demonstrated that patients with BPH who take TZ/AZ/DZ have a lower risk for developing PD than those who take tamsulosin."

Journal • Retrospective data • Review • Benign Prostatic Hyperplasia • CNS Disorders • Movement Disorders • Parkinson's Disease • ADRA1B

A MOF-Templated Double-Shelled Co3O4/NiCo2O4 Nanocomposite for Electrochemical Detection of Alfuzosin. (PubMed, Nanomaterials (Basel)) - "The sensor was successfully applied to determine the AFZ in pharmaceutical tablets and human serum samples, with satisfactory recoveries. Our results suggest that the double-shelled Co3O4/NiCo2O4 nanocomposite is a promising material for the fabrication of electrochemical sensors for AFZ detection."

Journal • Benign Prostatic Hyperplasia

Utilization of absorbance subtraction and ratio difference green spectrophotometric methods for the quantification of alfuzosin hydrochloride and tadalafil in their binary mixture. (PubMed, BMC Chem) - "The methods used were verified in accordance with the recommendations of the ICH and demonstrated adequate linear regression in working ranges of 1-15 µg/mL for alfuzosin hydrochloride and 3-40 µg/mL for tadalafil. The methods were accurate, precise, and selectively employed to quantify alfuzosin hydrochloride and tadalafil in their combined tablets."

Journal • Benign Prostatic Hyperplasia

In-Vivo Acute Ureteral Dilation using Electromotive Drug Administration (EMDA) in the Porcine Ureter (AUA 2024) - "In each of six pigs, in one ureter, an EMDA catheter was activated while alfuzosin 10 mg, isoproterenol 1 mg, or aminophylline 500 mg each diluted in 100 ml sterile water were infused at 5 ml/min for 20 minutes. In the porcine ureter, EMDA administration of alfuzosin significantly increased ureteral distensibility."

Preclinical • Urolithiasis

BE24-005: Multiple Dose, Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets Under Fed Conditions (clinicaltrials.gov) - P1 | N=44 | Not yet recruiting | Sponsor: Pharma Nueva

New P1 trial

Effect of different alpha-receptor antagonists on metabolic parameters: a head-to-head comparison. (PubMed, Int Urol Nephrol) - "Although these results do not support previous findings that tamsulosin has adverse effects on metabolic parameters, they suggest that doxazosin treatment may be a reason for preference in patients with BPH or LUTS accompanied by metabolic disorder."

Head-to-Head • Journal • Benign Prostatic Hyperplasia • Dyslipidemia • Metabolic Disorders • ADRA1B

The Bioequivalence Study of Alfuzosin 10 mg Prolong-released Tablets Under Fed Conditions (clinicaltrials.gov) - P1 | N=44 | Not yet recruiting | Sponsor: International Bio service

New P1 trial

Evaluation of the effect of Alfuprost MR on detrusor thickness and bladder mass in patients with detrusor hypertrophy caused by benign prostatic hyperplasia (PubMed, Urologiia) - "During the 24-week treatment of patients with BPH, Alfuprost MR demonstrated clinical efficacy not only in reducing voiding symptoms and in improving the QoL, but also a positive effect on detrusor hypertrophy, as evidenced by changes in detrusor thickness and bladder mass index. The absence of any adverse events, including decrease in blood pressure and heart rate, allows us to recommend Alfuprost MR as an effective treatment for LUTS associated with BPH, which reduces detrusor hypertrophy and has a high safety profile and minimal vasodilating effects."

Journal • Benign Prostatic Hyperplasia • Hypotension

Impact of Nonselective and Selective α-1 Adrenergic Blockers on the Sedative Efficacy of Dexmedetomidine in Urologic Surgery: A Prospective, Observational Study. (PubMed, Med Sci Monit) - "BACKGROUND This study aimed to compare the impact of a-1 adrenergic blockers - nonselective (alfuzosin, doxazosin, and terazosin) and selective (silodosin and tamsulosin) - on the sedative effects of the alpha-2 adrenergic agonist dexmedetomidine (DMT) in patients undergoing urologic surgery. CONCLUSIONS Nonselective alpha-1 adrenergic blockers can reduce the sedative effects of DMT. Consequently, there may be a need for individualized anesthesia management considering the specific subtype of alpha-1 adrenergic blocker medication."

Journal • Observational data • Surgery • Anesthesia • Urology

Structure-Guided Discovery of N-CAIR Mutase Inhibitors. (PubMed, Biochemistry) - "Several of these compounds, including the α-blocker Alfuzosin, inhibit the microbial PurE enzymes much more effectively than the human homologue. These structures and the newly described PurE inhibitors are valuable tools to aid in further studies of this enzyme and provide a foundation for the development of compounds that target differences between human and microbial purine metabolism."

Journal

Ureteral Stent Related Symptoms and Pharmacotherapy : A Brief Narrative Review. (PubMed, J Clin Pharmacol) - "Most of them show a clear benefit of alpha blockers,particularly alfuzosin on treating urinary stent related symptoms and hence there is a strong recommendation for the use of alpha blockers for the treatment of Stent Related Symptoms (srs) in the guidelines of European Association of Urology. Anticholinergics and mirabegron have shown a significant benefit in dealing with irritative bladder symptoms. On the contrary,the findings on combination therapies are contradicting, with some studies showing that combination therapy is not superior to monotherapy regarding most of the subsets of Ureteral Stent Symptom Questionnaire (USSQ), while others present a clear benefit of combination therapies specifically silodosin and solifenacin in treating stent associated Lower Urinary Tract Symptoms (LUTS) than any other type of monotherapy or combination therapy...However, there are conflicting evidence concerning most other types of medical treatment. . Randomised trials with..."

Journal • Review • Urology

Comparing effects of alpha-blocker management on acute urinary retention secondary to benign prostatic hyperplasia: A systematic review and network meta-analysis. (PubMed, Prostate Int) - "Compared to placebo, alfuzosin, silodosin, tamsulosin, and alfuzosin plus tamsulosin resulted in significantly higher TWOC success rates, whereas doxazosin did not show a significant difference in TWOC success rate compared to placebo. Alpha blockers may increase the success rate of TWOC. This study evaluated the priority of the effect of several alpha-blocker regimens on AUR related to BPH, which is expected to be helpful in selecting the best medication for patients with AUR."

Journal • Retrospective data • Review • Benign Prostatic Hyperplasia

Clinical and Urodynamic Predictors for Failure of Medical Management with Alpha Blockers in PBNO: A Retrospective Cohort Analysis. (PubMed, Urology) - "Alpha-blockers are more likely to fail in PBNO in younger patients generating higher voiding pressures and BOOI > 60."

Journal • Retrospective data

Electronic medical records-based retrospective, longitudinal, observational study to understand the patient management of benign prostatic hyperplasia with alpha-blockers monotherapy in Indian population. (PubMed, Urol Ann) - "Of the total AEs, patients in the alfuzosin, silodosin, tamsulosin, and prazosin groups experienced 21%, 22%, 39%, and 18% of AEs, respectively. The nonselective alpha-adrenergic receptor antagonist, alfuzosin, emerged as noninferior in effectiveness and superior in tolerability than other selective alpha-blockers, silodosin, tamsulosin, and prazosin."

Journal • Monotherapy • Observational data • Retrospective data • Benign Prostatic Hyperplasia